Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PDE5i Use in Renal Transplant Recipients
NCT04122105Withdrawn
- Sponsor
- University of British Columbia
- Start
- Apr 2021
- Primary completion
- Jan 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Randomised, open-label trial of sildenafil in ischemia-reperfusion injury (IRI) (2 arms), sponsored by University of British Columbia. Primary endpoint: Renal transplant function within 90 days postop. Planned start Apr 2021; status: withdrawn.
02
Drugs
sildenafil
03
Conditions
ischemia-reperfusion injury (IRI)
Beyond the preview
Go deeper on NCT04122105.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04122105.